These findings indicated that exosomes were important mediators for tumor cells to discard adverse factors and remodel a favorable niche, and revealed that miR-184-3p and hnRNPA2B1 represent the new therapeutic targets for TNBCs. Here, HNRNPA2B1 is linked to neoplasm.